JP2024520142A5 - - Google Patents
Info
- Publication number
- JP2024520142A5 JP2024520142A5 JP2023574549A JP2023574549A JP2024520142A5 JP 2024520142 A5 JP2024520142 A5 JP 2024520142A5 JP 2023574549 A JP2023574549 A JP 2023574549A JP 2023574549 A JP2023574549 A JP 2023574549A JP 2024520142 A5 JP2024520142 A5 JP 2024520142A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical product
- product according
- breast cancer
- olaparib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195795P | 2021-06-02 | 2021-06-02 | |
| US63/195,795 | 2021-06-02 | ||
| PCT/EP2022/064697 WO2022253800A1 (en) | 2021-06-02 | 2022-05-31 | Methods of treating breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520142A JP2024520142A (ja) | 2024-05-21 |
| JP2024520142A5 true JP2024520142A5 (https=) | 2025-06-09 |
Family
ID=82117716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574549A Withdrawn JP2024520142A (ja) | 2021-06-02 | 2022-05-31 | 乳癌を処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240269135A1 (https=) |
| EP (1) | EP4346828A1 (https=) |
| JP (1) | JP2024520142A (https=) |
| KR (1) | KR20240016344A (https=) |
| CN (1) | CN118139624A (https=) |
| AU (1) | AU2022286616A1 (https=) |
| BR (1) | BR112023025003A2 (https=) |
| CA (1) | CA3220751A1 (https=) |
| CL (1) | CL2023003533A1 (https=) |
| IL (1) | IL308684A (https=) |
| MX (1) | MX2023014420A (https=) |
| WO (1) | WO2022253800A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
-
2022
- 2022-05-31 CA CA3220751A patent/CA3220751A1/en active Pending
- 2022-05-31 US US18/564,778 patent/US20240269135A1/en active Pending
- 2022-05-31 EP EP22732066.0A patent/EP4346828A1/en not_active Withdrawn
- 2022-05-31 KR KR1020237045312A patent/KR20240016344A/ko not_active Withdrawn
- 2022-05-31 MX MX2023014420A patent/MX2023014420A/es unknown
- 2022-05-31 JP JP2023574549A patent/JP2024520142A/ja not_active Withdrawn
- 2022-05-31 WO PCT/EP2022/064697 patent/WO2022253800A1/en not_active Ceased
- 2022-05-31 CN CN202280039309.4A patent/CN118139624A/zh active Pending
- 2022-05-31 BR BR112023025003A patent/BR112023025003A2/pt not_active Application Discontinuation
- 2022-05-31 IL IL308684A patent/IL308684A/en unknown
- 2022-05-31 AU AU2022286616A patent/AU2022286616A1/en not_active Abandoned
-
2023
- 2023-11-28 CL CL2023003533A patent/CL2023003533A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heist et al. | Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer | |
| JP2012522837A5 (https=) | ||
| EP3177311B1 (en) | Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma | |
| CN108135901A (zh) | 胆管癌的治疗 | |
| JP2014515373A5 (https=) | ||
| JP6462147B2 (ja) | Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用 | |
| WO2015185011A1 (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
| Jiang et al. | Progress in the treatment of lung adenocarcinoma by integrated traditional Chinese and Western medicine | |
| JP2024533423A5 (https=) | ||
| CN115135649A (zh) | 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 | |
| JP2022526159A5 (https=) | ||
| Chai et al. | First-line chemoradiation with or without chidamide (tucidinostat) in patients with intermediate-and high-risk early-stage extranodal nasal-type natural killer/T-cell lymphoma: a randomized phase 2 study in China | |
| JP2024539476A5 (https=) | ||
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| CN115463118A (zh) | 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途 | |
| JP2024520142A5 (https=) | ||
| JP2024520567A (ja) | 肺線維症の予防または治療用の薬学製剤 | |
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| JP7142707B2 (ja) | ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤 | |
| Stellamans et al. | Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial | |
| JP2024532129A5 (https=) | ||
| SAFFARIEH et al. | Incidence of shivering and analgesic quality and complications after cesarean section under spinal anesthesia with or without intrathecal sufentanil and tramadol. | |
| CN121102377B (zh) | 含首荟通便胶囊的用于治疗结直肠癌的药物组合物及其应用 | |
| CN103860561B (zh) | 一种防治乳腺癌的药物组合物及其应用 | |
| Bera et al. | Concurrent chemoradiation with paclitaxel in locally advanced head and neck cancer: A feasibility study from tertiary cancer care center |